FREEDOM-C Trial Of Oral Treprostinil In Pulmonary Arterial Hypertension Fails To Meet Primary Endpoint United Therapeutics Corporation (Nasdaq: UTHR) announced the results of the FREEDOM-C trial of oral treprostinil, a sustained-release formulation of treprostinil, in pulmonary arterial hypertension (PAH). Preliminary analysis demonstrates that the trial did not achieve statistical significance for the primary endpoint, six minute walk (6MW) distance at Week 16.
Death Toll From Uncontrolled Blood Pressure In Ethnic Populations The Prevalence Of Racial And Ethnic Disparities Two studies in the current issue examine ethnic and racial disparities in hypertension care and control, and accompanying commentaries from three distinguished editorialists amplify and elucidate this important topic. In the first study, Fiscella and Holt find that racial disparities in blood pressure control contribute to nearly 8,000 preventable deaths from heart disease and stroke among blacks every year.
Use of this online service signifies your agreement to our disclaimer, privacy policy, and terms of use, which you should read, or have read before going further.
